Preliminary investigations of plasma lipidome and selenium levels in adults with treated hypothyroidism and in healthy individuals without selenium deficiency.

The great advantage of our work is that we follow very strict criteria for qualifying patients for the research. It is rare in patients suffering from hypothyroidism for the lipid profile—usually routinely prescribed for patients (total cholesterol, LDL, HDL, TG)- for glucose and insulin levels to be within the accepted norms. The exclusion of the most common fluctuations in biochemical parameters and the well-controlled levels of thyroid hormones in the study group is the basis for suspecting that individual species of the lipidome are typical of hypothyroidism itself, perfectly compensated without comorbidities. Both studied, and the control groups were age- and BMI-matched. Moreover, there were no statistically significant differences in TC, LDL-C, HDL-C, TGs, glucose/insulin, and degree of insulin resistance. We ensured that all participants in the study were not taking any medication, and dietary supplements that could affect the lipid profile. The project participants came from the same geographical region and were on a similar diet. We indicated that the hypothyroid group had lower levels of Se than the controls (the normal concentration in adult human blood serum is between 110 and 165 mcg/L). There is a lack of such current data on this specific human population. In the state of selenium deficiency associated with loss of glutathione peroxidase activity, the serum concentration is usually below 40 mcg/L 83 . We assessed selenium status by measuring plasma selenium, which responds to changes in intake. It is essential to note that while selenium plays a role in thyroid function, not everyone with hypothyroidism will have its deficiency, and the relationship between the two can vary from person to person. In our study, we eliminated the results of patients whose selenium levels would have indicated a severe deficiency. The study’s weakness is the small sample size, especially the control group. During recruitment for the study, many volunteers had to be excluded due to the diagnosis of other diseases. It also turned out that it was challenging to select a group of people who would meet the rigorous qualification criteria for our project. The power of our study is relatively low. However, the data acquired here may be considered preliminary for broader research. Interactions with other nutrients, such as vitamins and some minerals, may also influence the effects of selenium on plasma lipids. We will examine this in the next stage of our project. Completing our future studies with the identified limitations may contribute to a deeper understanding of the complex relationship between Se and lipids’ metabolism and its modification by various thyroid pathologies. Moreover, considering that the biological effects and bioavailability of Se may strongly depend on its chemical forms and their amounts in diet 84 , 85 , our research could be extended to investigate speciation forms of that element and their distribution in different tissues, as well as their response to varying dietary selenium content.

The cross-sectional cohort study was initiated in 2021. The study protocol received ethical approval from the Medical University of Lublin Bioethics Committee (KE-0254/7/2021). Informed consent was obtained in writing from each participant. The study was conducted in accordance with the principles of the Declaration of Helsinki. The patients included in the study had a diagnosis of either Hashimoto’s disease or non-autoimmune hypothyroidism (Hypo-non-Hashimoto), according to endocrinological assessment. This study investigated plasma lipidome in 24 HT patients with autoimmune hypothyroidism, 11 non-HT patients with hypothyroidism without autoimmune thyroiditis, and 6 age-, sex-, and body mass index (BMI)-matched healthy controls. Subjects were recruited from a specialized thyroid outpatient unit with higher frequencies of thyroid disorders than in the general population. The control group consisted of individuals with normal thyroid function. Thyroid-stimulating hormone (TSH), free T4 (fT4), free T3 (fT3), serum lipid profile, fasting glucose, and fasting insulin were measured. Thyroid peroxidase antibody (TPOAb) and antithyroglobulin antibody (TgAb) were assessed to confirm autoimmune thyroiditis in patients with Hashimoto’s disease. Patients with either Hashimoto’s disease or non-autoimmune hypothyroidism were receiving thyroid hormone replacement therapy with levothyroxine (LT4) in tablets (doses of LT4 are shown in Tables 1 and 2 ). Table 1 Clinical profile of participating subjects with Hashimoto’s disease. Variable Hashimoto’s disease Valid N Mean Median Minimum Maximum Lower quartile Upper quartile Quartile range Std. dev Age (years) 24 33.500 29.500 22.000 59.000 23.000 43.000 20.00 11.527 BMI (kg/m 2 ) 24 23.865 23.420 17.710 35.010 20.660 26.730 6.070 4.346 LT4 dose (µg) 24 75.682 75.000 12.500 137.000 56.250 100.000 43.750 30.362 Hypothyroidism (years) 24 5.750 5.000 1.000 19.000 2.500 8.000 5.500 4.406 TSH (uIU/mL) 24 1.989 1.910 0.870 3.795 1.550 2.380 0.830 0.722 fT4 (ng/dL) 24 1.180 1.100 0.810 1.710 0.970 1.410 0.440 0.269 fT3 (pg/mL) 24 2.983 2.985 2.040 4.650 2.445 3.415 0.970 0.6360 Total cholesterol (mg/dL) 24 173.741 175.500 98.000 245.000 158.500 188.500 30.000 31.957 HDL cholesterol (mg/dL) 24 62.715 63.500 39.000 98.000 55.200 68.500 13.300 14.062 LDL cholesterol (mg/dL) 24 92.081 92.600 49.000 147.200 67.900 105.800 37.900 25.080 Triglycerides (mg/dL) 24 89.226 96.000 36.000 142.000 61.500 114.000 52.500 31.058 AIP 24 0.135 0.149 -0.142 0.430 0.004 0.289 0.280 0.171 Fasting glucose (mg/dL) 24 88.271 89.000 77.000 98.000 83.500 92.000 8.500 5.651 Fasting insulin (mIU/L) 24 8.313 9.300 3.000 12.000 5.960 10.300 4.340 2.583 HOMA-IR 24 1.821 1.962 0.578 2.667 1.354 2.347 0.993 0.591 Se (µg/L) 24 89.993 93.805 53.660 122.200 76.300 101.700 25.400 20.251 Lipid species lysoPC a C14:0 24 2.111 1.970 1.120 4.110 1.575 2.310 0.735 0.755 lysoPC a C16:0 24 126.458 127.000 88.800 174.000 113.500 137.000 23.500 21.833 lysoPC a C16:1 24 2.940 2.885 1.760 4.810 2.430 3.305 0.875 0.708 lysoPC a C17:0 24 2.083 2.095 0.853 3.360 1.775 2.435 0.660 0.557 lysoPC a C18:0 24 39.338 39.150 19.700 53.800 34.700 46.500 11.800 8.537 lysoPC a C18:1 24 29.242 30.000 13.200 39.500 25.250 34.600 9.350 6.854 lysoPC a C18:2 24 40.404 39.600 12.000 66.400 30.850 51.250 20.400 13.928 lysoPC a C20:3 24 2.545 2.565 1.440 3.560 2.200 2.940 0.740 0.594 lysoPC a C20:4 24 7.774 7.425 3.790 11.900 6.350 9.050 2.700 2.173 lysoPC a C24:0 24 0.214 0.201 0.086 0.576 0.156 0.246 0.090 0.099 lysoPC a C26:0 24 0.332 0.233 0.134 1.330 0.188 0.381 0.193 0.255 lysoPC a C26:1 24 0.216 0.153 0.088 0.886 0.123 0.236 0.112 0.171 lysoPC a C28:0 24 0.299 0.247 0.144 0.955 0.200 0.332 0.132 0.169 lysoPC a C28:1 24 0.431 0.403 0.186 1.220 0.296 0.503 0.207 0.217 PC aa C24:0 24 50.577 50.692 0.083 101.000 0.138 101.000 100.862 51.507 PC aa C26:0 24 80.237 101.000 0.841 101.000 101.000 101.000 0.000 41.345 PC aa C28:1 24 2.727 2.845 1.480 3.870 2.170 3.180 1.0100 0.755 PC aa C30:0 24 3.775 3.680 1.860 10.300 2.820 4.220 1.40 1.801 PC aa C30:2 24 101.000 101.000 101.000 101.000 101.000 101.000 0.000 0.000 PC aa C32:0 24 12.525 12.150 7.700 25.800 10.200 14.050 3.850 3.644 PC aa C32:1 24 13.434 11.550 5.460 43.600 8.610 15.800 7.190 7.953 PC aa C32:2 24 2.854 2.735 0.966 5.900 1.960 3.425 1.465 1.236 PC aa C32:3 24 0.353 0.366 0.203 0.534 0.286 0.413 0.127 0.085 PC aa C34:1 24 207.667 198.000 116.000 457.000 171.500 220.500 49.000 64.836 PC aa C34:2 24 426.958 416.000 258.000 668.000 348.500 484.000 135.500 95.442 PC aa C34:3 24 13.174 12.450 7.310 23.600 11.000 14.750 3.7500 3.901 PC aa C34:4 24 1.428 1.330 0.489 3.650 0.978 1.555 0.5770 0.726 PC aa C36:0 24 1.087 1.075 0.198 2.060 0.765 1.450 0.6850 0.519 PC aa C36:1 24 39.442 38.200 24.200 82.200 31.700 44.050 12.350 12.060 PC aa C36:2 24 212.833 215.500 127.000 280.000 169.000 256.500 87.500 48.007 PC aa C36:3 24 105.892 100.650 59.700 167.000 87.600 111.500 23.900 27.680 PC aa C36:4 24 168.125 158.500 87.000 316.000 141.500 174.500 33.000 49.408 PC aa C36:5 24 18.322 16.950 7.750 59.200 13.150 21.500 8.350 10.006 PC aa C36:6 24 0.664 0.679 0.242 1.730 0.500 0.772 0.2720 0.2911 PC aa C38:0 24 2.366 2.200 1.540 3.750 1.825 2.780 0.955 0.693 PC aa C38:1 24 0.511 0.526 0.195 1.010 0.343 0.641 0.2980 0.205 PC aa C38:3 24 31.929 30.500 22.000 60.800 26.900 34.300 7.40 8.316 PC aa C38:4 24 78.104 74.350 49.200 146.000 64.650 86.600 21.950 20.336 PC aa C38:5 24 36.438 34.900 20.800 85.400 32.750 37.950 5.200 11.530 PC aa C38:6 24 64.133 59.150 29.900 140.000 46.800 71.200 24.400 23.620 PC aa C40:1 24 96.807 101.000 0.371 101.000 101.000 101.000 0.000 20.540 PC aa C40:2 24 0.173 0.174 0.096 0.264 0.148 0.192 0.044 0.039 PC aa C40:3 24 0.324 0.306 0.237 0.470 0.259 0.364 0.104 0.075 PC aa C40:4 24 1.893 1.795 0.955 4.520 1.480 2.105 0.625 0.6561 PC aa C40:5 24 5.324 4.900 3.380 16.900 4.255 5.445 1.190 2.5760 PC aa C40:6 24 18.375 16.400 10.800 52.000 13.500 19.550 6.050 8.589 PC aa C42:0 24 0.365 0.319 0.201 0.648 0.297 0.434 0.136 0.116 PC aa C42:1 24 0.172 0.166 0.090 0.289 0.121 0.216 0.094 0.055 PC aa C42:2 24 0.138 0.135 0.075 0.195 0.108 0.169 0.061 0.035 PC aa C42:4 24 0.105 0.105 0.063 0.167 0.095 0.119 0.025 0.025 PC aa C42:5 24 0.207 0.202 0.112 0.403 0.165 0.232 0.066 0.060 PC aa C42:6 24 0.236 0.227 0.146 0.444 0.201 0.260 0.059 0.063 PC ae C30:0 24 0.367 0.363 0.157 0.548 0.305 0.425 0.120 0.095 PC ae C30:1 24 71.574 101.000 0.016 101.000 0.243 101.000 100.757 46.842 PC ae C30:2 24 0.084 0.079 0.043 0.173 0.065 0.100 0.0355 0.029 PC ae C32:1 24 2.493 2.365 1.520 3.930 2.040 2.905 0.8650 0.597 PC ae C32:2 24 0.600 0.602 0.346 0.840 0.477 0.719 0.242 0.147 PC ae C34:0 24 1.086 1.030 0.523 2.070 0.909 1.175 0.260 0.321 PC ae C34:1 24 8.873 8.605 5.700 11.500 7.950 10.300 2.350 1.628 PC ae C34:2 24 11.637 12.050 5.840 17.300 8.650 13.850 5.200 3.243 PC ae C34:3 24 7.165 7.200 4.600 10.700 5.530 8.165 2.635 1.835 PC ae C36:0 24 0.561 0.583 0.380 0.806 0.451 0.664 0.213 0.122 PC ae C36:1 24 5.924 5.930 3.440 8.360 4.750 6.710 1.960 1.252 PC ae C36:2 24 11.070 11.200 6.530 16.100 8.875 13.100 4.225 2.584 PC ae C36:3 24 6.450 6.365 3.850 9.770 4.825 7.630 2.805 1.792 PC ae C36:4 24 16.777 17.000 7.240 28.800 12.300 20.300 8.000 5.047 PC ae C36:5 24 10.198 9.750 5.410 16.300 7.950 12.900 4.950 2.868 PC ae C38:0 24 1.422 1.370 0.854 2.370 1.240 1.615 0.375 0.323 PC ae C38:1 24 25.376 0.185 0.015 101.000 0.111 50.698 50.587 44.600 PC ae C38:2 24 1.011 1.000 0.611 1.580 0.870 1.120 0.250 0.2441 PC ae C38:3 24 2.414 2.390 1.500 3.340 2.160 2.740 0.580 0.474 PC ae C38:4 24 9.718 9.270 6.020 16.300 8.355 11.050 2.695 2.396 PC ae C38:5 24 14.589 15.050 9.940 22.500 11.250 17.500 6.250 3.424 PC ae C38:6 24 6.080 6.005 2.990 9.270 4.760 7.265 2.5050 1.673 PC ae C40:1 24 0.831 0.815 0.558 1.340 0.703 0.930 0.22 0.185 PC ae C40:2 24 1.242 1.215 0.632 1.810 0.933 1.455 0.522 0.33 PC ae C40:3 24 0.619 0.587 0.403 0.889 0.553 0.670 0.116 0.121 PC ae C40:4 24 1.454 1.385 0.859 2.540 1.300 1.555 0.255 0.364 PC ae C40:5 24 2.186 2.095 1.430 3.360 1.925 2.370 0.445 0.463 PC ae C40:6 24 2.983 2.880 1.880 4.860 2.435 3.375 0.940 0.760 PC ae C42:0 24 75.868 101.000 0.396 101.000 50.782 101.000 50.218 44.466 PC ae C42:1 24 0.185 0.184 0.118 0.272 0.158 0.214 0.055 0.040 PC ae C42:2 24 0.337 0.314 0.235 0.570 0.285 0.374 0.089 0.080 PC ae C42:3 24 0.479 0.473 0.222 0.691 0.413 0.578 0.165 0.116 PC ae C42:4 24 8.947 0.549 0.346 101.000 0.506 0.710 0.204 28.352 PC ae C42:5 24 1.492 1.365 0.874 2.580 1.255 1.695 0.440 0.407 PC ae C44:3 24 0.066 0.065 0.035 0.103 0.053 0.077 0.024 0.018 PC ae C44:4 24 0.244 0.220 0.114 0.421 0.208 0.282 0.074 0.072 PC ae C44:5 24 1.300 1.230 0.694 2.380 1.090 1.435 0.345 0.376 PC ae C44:6 24 0.789 0.748 0.423 1.460 0.658 0.863 0.205 0.251 SM (OH) C14:1 24 4.746 4.575 2.720 7.070 3.725 5.975 2.250 1.308 SM (OH) C16:1 24 2.448 2.410 1.410 3.790 2.050 2.830 0.780 0.661 SM (OH) C22:1 24 7.929 7.840 5.000 11.000 6.690 9.035 2.345 1.741 SM (OH) C22:2 24 7.336 7.105 5.040 10.400 5.825 9.050 3.225 1.647 SM (OH) C24:1 24 0.740 0.721 0.450 1.110 0.605 0.836 0.2305 0.178 SM C16:0 24 97.396 94.750 64.900 130.000 84.250 112.500 28.25 17.964 SM C16:1 24 12.260 11.750 8.090 17.100 9.635 14.650 5.015 2.7261 SM C18:0 24 17.160 16.600 9.540 24.300 14.250 20.550 6.300 4.2460 SM C18:1 24 7.770 7.410 4.550 11.300 6.305 9.125 2.820 1.8818 SM C20:2 24 0.205 0.178 0.069 0.376 0.140 0.266 0.126 0.0894 SM C22:3 24 101.000 101.000 101.000 101.000 101.000 101.000 0.000 0.0000 SM C24:0 24 12.099 11.750 8.220 20.500 10.450 13.600 3.150 2.591 SM C24:1 24 39.229 39.950 26.000 61.600 33.150 44.550 11.400 7.856 SM C26:0 24 0.088 0.089 0.016 0.141 0.065 0.109 0.044 0.029 SM C26:1 24 0.234 0.233 0.105 0.373 0.178 0.280 0.102 0.067 Abbreviations of lipid species: Lysophosphatidylcholine with acyl residue (lysoPC a); Phosphatidylcholine with diacyl residue (PC aa); Phosphatidylcholine with acyl-alkyl residue (PC ae); Hydroxysphingomyelin with acyl residue (SM (OH)); Sphingomyelin with acyl residue (SM). Table 2 Clinical profile of participating subjects with non-autoimmune hypothyroidism. Variable Non-autoimmune hypothyroidism (Hypo-no-Hashimoto) Valid N Mean Median Minimum Maximum Lower quartile Upper quartile Quartile range Std. dev Age (years) 11 29.273 24.000 21.000 43.000 22.000 38.000 16.000 8.343 BMI (kg/m 2 ) 11 23.072 24.510 19.000 25.820 19.840 25.350 5.510 2.711 LT4 dose (µg) 11 47.074 50.000 25.000 75.000 28.570 57.140 28.570 16.290 Hypothyroidism (years) 11 4.000 2.000 1.000 12.000 1.000 8.000 7.000 4.242 TSH (uIU/mL) 11 1.663 1.680 0.704 2.674 1.140 2.230 1.090 0.590 fT4 (ng/dL) 11 2.071 1.320 0.850 9.930 1.190 1.520 0.330 2.614 fT3 (pg/mL) 11 3.175 2.980 2.410 4.050 2.730 3.730 1.000 0.583 Total cholesterol (mg/dL) 11 164.273 164.000 134.000 202.000 152.000 174.000 22.000 18.810 HDL cholesterol (mg/dL) 11 58.182 57.000 48.000 89.000 49.000 59.000 10.000 12.015 LDL cholesterol (mg/dL) 11 90.900 92.500 69.600 134.000 73.000 97.200 24.200 18.397 Triglycerides (mg/dL) 11 87.000 89.000 36.000 123.000 70.000 105.000 35.000 24.157 AIP 11 0.163 0.225 -0.393 0.400 0.089 0.265 0.176 0.205 Fasting glucose (mg/dL) 11 88.091 86.000 80.000 101.000 82.000 93.000 11.000 6.876 Fasting insulin (mIU/L) 11 8.120 7.600 4.600 10.920 6.400 9.830 3.430 2.058 HOMA-IR 11 1.769 1.558 1.034 2.508 1.422 2.230 0.807 0.489 Se (µg/L) 11 84.593 82.500 45.550 126.667 57.917 100.250 42.333 27.545 Lipid species lysoPC a C14:0 11 1.782 1.540 1.020 3.180 1.290 2.170 0.880 0.705 lysoPC a C16:0 11 110.064 106.000 79.300 149.000 98.200 122.000 23.800 18.653 lysoPC a C16:1 11 2.618 2.450 1.780 4.920 1.960 3.020 1.060 0.886 lysoPC a C17:0 11 1.894 1.850 1.420 2.640 1.500 2.260 0.760 0.411 lysoPC a C18:0 11 33.227 35.800 18.500 44.900 25.800 39.300 13.500 8.256 lysoPC a C18:1 11 24.682 23.900 17.400 31.600 18.900 30.200 11.300 5.224 lysoPC a C18:2 11 31.736 31.600 13.900 50.000 28.000 38.200 10.200 10.055 lysoPC a C20:3 11 2.028 1.830 1.050 4.280 1.390 2.520 1.130 0.883 lysoPC a C20:4 11 6.275 5.950 3.850 8.740 4.840 8.230 3.390 1.833 lysoPC a C24:0 11 0.258 0.216 0.127 0.493 0.202 0.321 0.119 0.106 lysoPC a C26:0 11 0.414 0.404 0.128 0.822 0.212 0.653 0.441 0.235 lysoPC a C26:1 11 0.239 0.177 0.097 0.541 0.139 0.392 0.253 0.140 lysoPC a C28:0 11 0.323 0.295 0.166 0.652 0.218 0.364 0.146 0.141 lysoPC a C28:1 11 0.500 0.476 0.202 0.915 0.327 0.618 0.291 0.216 PC aa C24:0 11 36.811 0.142 0.076 101.000 0.124 101.000 100.876 50.890 PC aa C26:0 11 46.407 1.110 0.849 101.000 0.874 101.000 100.126 52.268 PC aa C28:1 11 2.611 2.600 1.990 4.120 2.060 2.970 0.910 0.619 PC aa C30:0 11 3.177 3.320 1.860 4.610 2.200 4.400 2.200 1.064 PC aa C30:2 11 101.000 101.000 101.000 101.000 101.000 101.000 0.000 0.000 PC aa C32:0 11 11.278 10.800 8.960 16.900 9.260 12.700 3.440 2.386 PC aa C32:1 11 11.562 11.200 4.920 23.800 7.860 13.300 5.440 5.405 PC aa C32:2 11 2.454 2.100 0.370 5.470 1.660 3.690 2.030 1.413 PC aa C32:3 11 0.330 0.305 0.203 0.553 0.238 0.442 0.204 0.115 PC aa C34:1 11 186.182 176.000 140.000 246.000 161.000 215.000 54.000 35.439 PC aa C34:2 11 383.091 375.000 321.000 485.000 356.000 404.000 48.000 43.532 PC aa C34:3 11 12.804 11.400 5.440 24.300 10.200 15.600 5.400 5.112 PC aa C34:4 11 1.179 0.947 0.343 2.410 0.818 1.750 0.932 0.650 PC aa C36:0 11 0.950 0.810 0.125 2.100 0.721 1.340 0.619 0.535 PC aa C36:1 11 34.600 35.200 27.200 43.500 28.100 38.900 10.800 5.939 PC aa C36:2 11 190.364 183.000 158.000 255.000 171.000 201.000 30.000 27.990 PC aa C36:3 11 96.245 88.700 66.400 124.000 85.800 111.000 25.200 16.881 PC aa C36:4 11 144.482 151.000 99.300 184.000 111.000 168.000 57.000 29.848 PC aa C36:5 11 18.834 16.800 9.370 33.900 13.200 24.100 10.900 7.238 PC aa C36:6 11 0.632 0.505 0.306 1.210 0.416 0.842 0.426 0.270 PC aa C38:0 11 2.074 2.000 1.460 3.140 1.670 2.230 0.560 0.557 PC aa C38:1 11 9.762 0.622 0.169 101.000 0.364 1.010 0.646 30.261 PC aa C38:3 11 28.336 25.500 18.200 41.500 23.100 37.600 14.500 7.390 PC aa C38:4 11 68.173 61.400 44.100 104.000 55.600 75.700 20.100 17.763 PC aa C38:5 11 34.509 34.200 23.700 51.000 26.500 40.800 14.300 7.814 PC aa C38:6 11 67.091 61.500 45.800 123.000 50.800 72.800 22.000 21.921 PC aa C40:1 11 91.854 101.000 0.391 101.000 101.000 101.000 0.000 30.334 PC aa C40:2 11 0.171 0.170 0.096 0.257 0.144 0.193 0.049 0.042 PC aa C40:3 11 0.319 0.309 0.224 0.448 0.270 0.348 0.078 0.063 PC aa C40:4 11 1.583 1.530 0.967 2.670 1.100 1.880 0.780 0.520 PC aa C40:5 11 4.902 4.220 2.800 9.340 3.810 5.760 1.950 1.809 PC aa C40:6 11 18.282 17.200 12.800 29.200 13.000 23.200 10.200 5.473 PC aa C42:0 11 0.364 0.328 0.252 0.703 0.306 0.379 0.073 0.119 PC aa C42:1 11 0.179 0.172 0.104 0.311 0.161 0.183 0.022 0.053 PC aa C42:2 11 0.139 0.131 0.106 0.198 0.112 0.165 0.053 0.028 PC aa C42:4 11 0.096 0.096 0.057 0.138 0.066 0.130 0.064 0.030 PC aa C42:5 11 0.214 0.206 0.148 0.366 0.155 0.247 0.092 0.068 PC aa C42:6 11 0.230 0.225 0.113 0.334 0.172 0.291 0.119 0.066 PC ae C30:0 11 0.334 0.311 0.207 0.475 0.251 0.412 0.161 0.092 PC ae C30:1 11 55.114 101.000 0.021 101.000 0.062 101.000 100.938 52.718 PC ae C30:2 11 0.084 0.085 0.051 0.118 0.067 0.099 0.032 0.018 PC ae C32:1 11 2.131 2.230 1.500 2.950 1.580 2.410 0.830 0.466 PC ae C32:2 11 0.532 0.507 0.452 0.737 0.454 0.592 0.138 0.090 PC ae C34:0 11 0.923 0.799 0.652 1.430 0.700 1.100 0.400 0.252 PC ae C34:1 11 8.244 7.730 5.710 11.400 6.590 9.860 3.270 1.917 PC ae C34:2 11 9.494 8.900 5.520 12.900 8.160 11.800 3.640 2.236 PC ae C34:3 11 6.322 5.490 4.210 11.200 4.960 7.350 2.390 1.988 PC ae C36:0 11 0.540 0.483 0.387 0.951 0.411 0.586 0.175 0.161 PC ae C36:1 11 5.577 5.680 3.850 7.570 4.220 7.010 2.790 1.350 PC ae C36:2 11 9.991 10.100 7.160 12.600 7.780 11.400 3.620 1.963 PC ae C36:3 11 5.029 4.740 3.070 6.630 4.350 6.210 1.860 1.082 PC ae C36:4 11 12.189 11.700 7.530 16.900 9.620 14.500 4.880 3.017 PC ae C36:5 11 8.080 7.530 5.170 14.600 5.990 9.470 3.480 2.718 PC ae C38:0 11 1.466 1.510 0.983 2.080 1.220 1.780 0.560 0.347 PC ae C38:1 11 36.861 0.276 0.068 101.000 0.171 101.000 100.829 50.850 PC ae C38:2 11 0.879 0.916 0.434 1.280 0.667 1.090 0.423 0.260 PC ae C38:3 11 2.224 2.300 1.060 3.010 1.910 2.690 0.780 0.583 PC ae C38:4 11 8.051 7.650 4.480 10.800 6.450 10.100 3.650 2.042 PC ae C38:5 11 11.657 11.500 8.610 16.700 9.390 13.500 4.110 2.553 PC ae C38:6 11 5.242 5.000 4.030 7.840 4.090 5.710 1.620 1.290 PC ae C40:1 11 0.779 0.717 0.550 1.160 0.670 0.890 0.220 0.173 PC ae C40:2 11 1.203 1.190 0.819 1.640 0.924 1.450 0.526 0.274 PC ae C40:3 11 0.588 0.575 0.412 0.781 0.460 0.730 0.270 0.129 PC ae C40:4 11 1.280 1.310 0.794 1.800 1.070 1.490 0.420 0.299 PC ae C40:5 11 1.946 1.880 1.390 3.060 1.480 2.340 0.860 0.517 PC ae C40:6 11 2.882 2.790 1.990 4.460 2.460 2.800 0.340 0.759 PC ae C42:0 11 55.321 101.000 0.388 101.000 0.473 101.000 100.527 52.480 PC ae C42:1 11 0.185 0.184 0.121 0.263 0.150 0.219 0.069 0.044 PC ae C42:2 11 0.336 0.321 0.246 0.558 0.290 0.340 0.050 0.082 PC ae C42:3 11 0.464 0.447 0.314 0.722 0.416 0.471 0.055 0.106 PC ae C42:4 11 0.526 0.517 0.335 0.724 0.443 0.604 0.161 0.123 PC ae C42:5 11 1.403 1.420 0.922 2.090 1.100 1.720 0.620 0.364 PC ae C44:3 11 0.074 0.073 0.042 0.111 0.048 0.096 0.048 0.024 PC ae C44:4 11 0.241 0.242 0.148 0.324 0.196 0.286 0.090 0.055 PC ae C44:5 11 1.247 1.220 0.526 1.980 0.919 1.570 0.651 0.434 PC ae C44:6 11 0.800 0.775 0.542 1.340 0.610 0.936 0.326 0.222 SM (OH) C14:1 11 4.487 4.140 2.970 6.940 3.710 5.590 1.880 1.236 SM (OH) C16:1 11 2.266 2.150 1.510 3.430 1.780 2.780 1.000 0.602 SM (OH) C22:1 11 7.995 7.380 5.200 15.000 6.270 8.840 2.570 2.681 SM (OH) C22:2 11 7.055 6.550 4.670 10.900 5.490 8.670 3.180 1.945 SM (OH) C24:1 11 0.711 0.665 0.419 1.320 0.559 0.824 0.265 0.242 SM C16:0 11 89.909 86.700 75.900 115.000 80.100 99.300 19.200 12.564 SM C16:1 11 11.305 10.600 9.020 15.100 9.920 12.600 2.680 1.853 SM C18:0 11 15.518 15.400 11.300 18.900 13.800 18.500 4.700 2.487 SM C18:1 11 6.884 6.800 4.470 8.980 5.990 7.770 1.780 1.382 SM C20:2 11 0.194 0.197 0.117 0.249 0.169 0.240 0.071 0.045 SM C22:3 11 101.000 101.000 101.000 101.000 101.000 101.000 0.000 0.000 SM C24:0 11 11.670 12.100 8.100 17.400 9.650 13.000 3.350 2.601 SM C24:1 11 36.964 36.100 28.700 45.100 32.100 43.000 10.900 5.440 SM C26:0 11 0.089 0.083 0.039 0.153 0.062 0.117 0.055 0.035 SM C26:1 11 0.229 0.212 0.132 0.421 0.171 0.262 0.091 0.081 Clinical profile of participating subjects with Hashimoto’s disease. Abbreviations of lipid species: Lysophosphatidylcholine with acyl residue (lysoPC a); Phosphatidylcholine with diacyl residue (PC aa); Phosphatidylcholine with acyl-alkyl residue (PC ae); Hydroxysphingomyelin with acyl residue (SM (OH)); Sphingomyelin with acyl residue (SM). Clinical profile of participating subjects with non-autoimmune hypothyroidism. The doses of levothyroxine were carefully selected (based on information such as patients’ weight, age, and other medical conditions) to maintain euthyreosis in hypothyroidic patients. There were no differences in the euthyroidic levels of TSH, fT4, and fT3 between both the hypothyroidic groups and the healthy control—see the results section. The study participants were not receiving any other medical treatment. All members of the control and study groups were from the same geographic area (central and south-eastern Poland). Neither the control nor the two groups with hypothyroidism presented any pathologies (except the hypofunction of the thyroid gland), and they had taken no mineral or vitamin supplements for at least 3 months before the samples for analysis were collected. They were not on any special diets during the tests. Other exclusion criteria included the presence of a chronic condition (particularly affecting the function of the thyroid gland or weight or limiting the patient’s ability to participate in the study), use of lipid-altering drugs, and refusal to give informed consent. Fasting blood specimens for lipidomic studies were collected from the patients and control groups into commercially available sterile anticoagulant-treated tubes, e.g., EDTA-treated (VACUETTE® K2E K2EDTA ) . For Se measurements blood plasma was obtained by centrifuging heparinized whole blood (VACUETTE® TUBE NH Trace Elements Sodium Heparin (Greiner-Bio-One, Austria). All blood samples were separated for plasma immediately after collection and stored in − 80 °C freezers until laboratory analyses. Serum was used for routine diagnostic measurements (such as cholesterol, insulin, and thyroid hormones). Serum was collected in non-anticoagulant sterile tubes with a serum separator. Serum levels of TC and TG were determined using enzymatic methods, and HDL-C was measured by immunoassay. The Friedewald formula using determined TC, HDL-C, and TG levels and the adopted TG-to-VLDL-C ratio was used to calculate the LDL-C level (LDL-C = TC – HDL-C – TG/5 (mg/dl)) 22 . We applied TMA because such an analytical approach has better sensitivity and quantitative abilities than untargeted approaches where the metabolic, including lipid species of interest, are not predefined 23 . The quantifications of 145 lipids (such as 40 acylcarnitines, 90 glycerophospholipids, and 15 sphingomyelins) were undertaken. AbsoluteIDQ p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria) analyzed metabolites. Sample preparation was performed following the manufacturer’s protocol. Briefly, 10 µl of plasma was pipetted onto the filter plate of the kit. Subsequently, 10 µl internal standards were added, and the plate was dried under a nitrogen stream. The samples were derivatized using phenylisothiocyanate and again dried under a nitrogen stream. Metabolites were extracted using 5 mm ammonium acetate in methanol and further diluted for LC–MS and FIA-MS experiments. Analyses were performed on an Agilent Infinity II 1290 HPLC coupled to an Agilent triple quadrupole mass spectrometer 6470 TQ LC/MS (Agilent Technologies, Santa Clara, CA, USA). Acquisition methods were set as provided by Absolute Biocrates for the p180 kit. Data acquisition was performed by Mass Hunter Acquisition B.10.0 (Agilent Technologies, Santa Clara, CA, USA). Data analysis was performed using MetIDQ (Biocrates, Innsbruck, Austria) and Mass Hunter Quantitative (Agilent Technologies, Santa Clara, CA, USA). The plasma samples were dissolved with the acidic treatment in the microwave-assisted digestion system Ethos Up—Advanced Microwave Digestion Labstation (Milestone Srl, Italy) with user-selectable output power (0–1800W with 1W increment). Microwave-assisted acid digestion of samples was performed using a polypropylene rotor equipped with high-pressure Teflon vessels. The samples after the thawing were homogenized by sonification (15 min) and vortexing (30 s). Next, the plasma samples underwent microwave mineralization with 3.5 mL of 65% HNO 3 Suprapur® grade and 1.5 mL of deionized water (DI water, conductivity < 0.08 µS/cm, HLP10 system, Hydrolab, Poland). The samples were dissolved with (DI) water up to a final volume of 7 mL. Solutions were stored at 4 °C prior to ICP-MS measurements. The selenium standard solution was made from an individual standard (1.000 mg/L, TraceCERT®, Switzerland), and the calibration curves were prepared within range in the range of 0.2–50 µg/L. All solutions were prepared in freshly rinsed vials (with 1:1 nitric acid and deionized water (DI) at least three times). After microwave digestion, the plasma samples were diluted in the solution of 6% HNO 3 in deionized water to reduce non-spectral interferences. The total contents of Se in the plasma samples were measured by XSeries 2 ICP-MS (Thermo Fisher Scientific, Bremen, Germany) with PlasmaLab software, equipped with a collision/reaction cell operated using 7% H 2 in He mixture gas (Linde Gaz Polska, Poland), used in conjunction with an ASX-510 autosampler (CETAC, Omaha, Nebraska, USA). The advantage of using ICP-MS is that it detects both organic and inorganic forms of Se in samples. Each sample was analyzed in triplicate, and the FullQuant analysis method was used to quantify the data. The linearity of the calibration curves was evaluated by the respective correlation coefficients (r2) = 0.9999; the LOD of the method was based on a 3 × standard deviation of 100 analytical blanks. To validate the method, the certified reference materials were used. We used both non-matrix matched CRMs – EP-H-2 (EnviroMAT Drinking Water), and EU-H-3 (EnviroMAT Waste Water) (SCP Science, Quebec, ON, Canada), as well as Seronorm™ Serum Seronorm Trace Elements serum L2 (Sero, Billingstad, Norway), where the concentration of Se was within the control range specified by the manufacturer (120–157 µg/L). Recoveries were in the range of 95.00–104.17% (Supplementary Table S1 ). Descriptive statistics were stratified by the presence of hypothyroidism. As the Kolmogorov–Smirnov and Lilliefors tests indicated that the variables were not normally distributed, the nonparametric Kruskal–Wallis ANOVA test was used for continuous variables. A multiple linear regression analysis was used to evaluate the association between the presence of hypothyroidism and plasma selenium levels as well as lipid species. All analyses were two-tailed, with a significance level of 0.05 and a power of 80%. Statistical analyses were performed using TIBCO Software Inc. (2017) Statistica, version 13.0.0.0 (TIBCO, Tulsa, OK, USA), licensed to the Medical University of Lublin.

A detailed characterization of the patients with Hashimoto’s disease or non-autoimmune hypothyroidism (Hypo-non-Hashimoto), as well as control, is presented in Tables 1 , 2 , and 3 , respectively. As the variables were not normally distributed and nonparametric median tests were used to compare samples, the mean and standard deviation values are presented only to completely characterize the study groups. All the groups were age-, sex-, and BMI-matched. There were no significant differences in TSH or free thyroid hormone (fT4 and fT3) levels between the two hypothyroid groups (which included patients adequately treated with levothyroxine to maintain euthyreosis) and the healthy control. Furthermore, there were no significant differences in lipid profile, including total cholesterol ( p  = 0.13), LDL-cholesterol ( p  = 0.94), HDL-cholesterol ( p  = 0.09), and triglycerides ( p  = 0.16), as well as fasting glucose ( p  = 0.23), fasting insulin ( p  = 0.79), and HOMA-IR ( p  = 0.87) values between the Hashimoto’s disease group, non-autoimmune hypothyroidism (Hypo-non-Hashimoto) group and the healthy control (data not shown graphically). Table 3 Clinical profile of the control group. Variable Control Valid N Mean Median Minimum Maximum Lower quartile Upper quartile Quartile range Std. dev Age (years) 6 27.167 23.000 23.000 45.000 23.000 26.000 3.000 8.818 BMI (kg/m 2 ) 6 21.707 22.130 18.670 25.380 18.730 23.200 4.470 2.630 TSH (uIU/mL) 6 1.585 1.460 1.040 2.520 1.320 1.710 0.390 0.509 fT4 (ng/dL) 6 1.333 1.350 0.990 1.550 1.320 1.440 0.120 0.188 fT3 (pg/mL) 6 3.235 3.295 2.990 3.360 3.110 3.360 0.250 0.151 Total cholesterol (mg/dL) 6 153.333 148.000 134.000 191.000 137.000 162.000 25.000 21.869 HDL cholesterol (mg/dL) 6 51.833 53.000 41.000 62.000 45.000 57.000 12.000 7.705 LDL cholesterol (mg/dL) 6 90.500 87.000 69.000 123.000 83.000 94.000 11.000 17.952 Triglycerides (mg/dL) 6 62.667 65.000 32.000 83.000 57.000 74.000 17.000 17.750 AIP 6 0.068 0.087 -0.108 0.216 0.000 0.127 0.127 0.113 Fasting glucose (mg/dL) 6 93.000 93.500 86.000 99.000 89.000 97.000 8.000 5.099 Fasting insulin (mIU/L) 6 7.700 7.850 4.400 10.400 5.600 10.100 4.500 2.576 HOMA-IR 6 1.772 1.812 0.967 2.469 1.341 2.228 0.887 0.607 Se (µg/L) 6 130.529 131.388 111.057 152.500 112.690 144.153 31.463 16.899 Lipid species lysoPC a C14:0 6 1.832 1.645 1.380 2.730 1.500 2.090 0.590 0.503 lysoPC a C16:0 6 121.383 126.000 85.300 143.000 116.000 132.000 16.000 20.018 lysoPC a C16:1 6 3.065 2.890 2.150 4.810 2.310 3.340 1.030 0.974 lysoPC a C17:0 6 1.890 1.815 1.530 2.510 1.550 2.120 0.570 0.377 lysoPC a C18:0 6 35.117 32.400 26.300 49.400 27.900 42.300 14.400 9.120 lysoPC a C18:1 6 30.483 31.450 21.300 41.000 25.400 32.300 6.900 6.739 lysoPC a C18:2 6 44.517 41.300 36.400 62.500 39.100 46.500 7.400 9.423 lysoPC a C20:3 6 2.553 2.705 1.880 2.970 2.090 2.970 0.880 0.465 lysoPC a C20:4 6 7.463 7.970 3.940 10.100 5.890 8.910 3.020 2.262 lysoPC a C24:0 6 0.231 0.191 0.126 0.491 0.154 0.236 0.082 0.134 lysoPC a C26:0 6 0.444 0.281 0.117 1.380 0.176 0.429 0.253 0.474 lysoPC a C26:1 6 0.284 0.193 0.094 0.750 0.122 0.351 0.229 0.248 lysoPC a C28:0 6 0.339 0.255 0.143 0.898 0.144 0.337 0.193 0.285 lysoPC a C28:1 6 0.440 0.295 0.208 1.140 0.210 0.492 0.282 0.361 PC aa C24:0 6 0.140 0.096 0.048 0.346 0.065 0.187 0.122 0.112 PC aa C26:0 6 0.889 0.699 0.409 1.920 0.415 1.190 0.775 0.589 PC aa C28:1 6 2.160 2.130 1.630 2.810 1.640 2.620 0.980 0.540 PC aa C30:0 6 2.517 2.460 1.890 3.600 2.030 2.660 0.630 0.614 PC aa C30:2 6 101.000 101.000 101.000 101.000 101.000 101.000 0.000 0.000 PC aa C32:0 6 9.858 9.980 7.540 11.600 9.350 10.700 1.350 1.410 PC aa C32:1 6 11.228 8.870 6.300 24.300 6.930 12.100 5.170 6.825 PC aa C32:2 6 2.400 1.910 1.560 4.840 1.570 2.610 1.040 1.254 PC aa C32:3 6 0.315 0.289 0.256 0.442 0.274 0.338 0.064 0.068 PC aa C34:1 6 186.500 189.000 118.000 260.000 142.000 221.000 79.000 53.902 PC aa C34:2 6 373.500 349.000 287.000 495.000 306.000 455.000 149.000 85.971 PC aa C34:3 6 12.067 10.195 7.370 22.400 8.340 13.900 5.560 5.604 PC aa C34:4 6 1.054 0.982 0.645 1.880 0.694 1.140 0.446 0.451 PC aa C36:0 6 0.620 0.483 0.392 1.170 0.441 0.750 0.309 0.297 PC aa C36:1 6 32.033 30.000 22.400 41.300 29.200 39.300 10.100 7.049 PC aa C36:2 6 184.500 171.000 149.000 268.000 164.000 184.000 20.000 42.486 PC aa C36:3 6 92.250 87.400 68.700 120.000 73.000 117.000 44.000 22.552 PC aa C36:4 6 134.750 147.500 71.500 159.000 129.000 154.000 25.000 32.686 PC aa C36:5 6 16.890 18.200 5.640 24.900 10.800 23.600 12.800 8.102 PC aa C36:6 6 0.528 0.476 0.258 0.908 0.298 0.753 0.455 0.265 PC aa C38:0 6 1.822 1.645 1.350 2.520 1.580 2.190 0.610 0.439 PC aa C38:1 6 0.436 0.413 0.249 0.766 0.290 0.482 0.192 0.183 PC aa C38:3 6 25.600 26.700 18.800 28.700 25.000 27.700 2.700 3.578 PC aa C38:4 6 64.033 69.650 32.100 83.800 51.200 77.800 26.600 19.486 PC aa C38:5 6 32.467 33.150 16.300 42.200 31.900 38.100 6.200 8.856 PC aa C38:6 6 50.883 48.400 33.800 71.900 41.100 61.700 20.600 13.851 PC aa C40:1 6 0.287 0.275 0.265 0.326 0.265 0.315 0.050 0.026 PC aa C40:2 6 0.164 0.163 0.099 0.229 0.110 0.221 0.111 0.054 PC aa C40:3 6 0.300 0.312 0.179 0.373 0.266 0.356 0.090 0.071 PC aa C40:4 6 1.538 1.665 0.819 1.900 1.420 1.760 0.340 0.387 PC aa C40:5 6 4.623 5.205 2.200 5.550 4.060 5.520 1.460 1.308 PC aa C40:6 6 14.200 13.700 8.700 22.500 11.400 15.200 3.800 4.659 PC aa C42:0 6 0.371 0.385 0.214 0.498 0.277 0.464 0.187 0.108 PC aa C42:1 6 0.177 0.167 0.114 0.242 0.153 0.218 0.065 0.046 PC aa C42:2 6 0.137 0.127 0.110 0.190 0.110 0.159 0.049 0.032 PC aa C42:4 6 0.106 0.114 0.060 0.130 0.100 0.120 0.020 0.024 PC aa C42:5 6 0.203 0.190 0.128 0.293 0.174 0.243 0.069 0.057 PC aa C42:6 6 0.237 0.226 0.162 0.311 0.191 0.303 0.112 0.061 PC ae C30:0 6 0.275 0.287 0.216 0.297 0.270 0.296 0.026 0.030 PC ae C30:1 6 0.089 0.089 0.000 0.242 0.000 0.114 0.114 0.089 PC ae C30:2 6 0.081 0.072 0.052 0.131 0.057 0.100 0.043 0.030 PC ae C32:1 6 1.982 1.810 1.410 2.750 1.600 2.510 0.910 0.529 PC ae C32:2 6 0.493 0.472 0.372 0.668 0.410 0.561 0.151 0.107 PC ae C34:0 6 0.795 0.814 0.627 0.922 0.681 0.914 0.233 0.126 PC ae C34:1 6 7.875 7.385 6.550 10.000 6.880 9.050 2.170 1.358 PC ae C34:2 6 9.303 9.570 7.290 11.600 7.490 10.300 2.810 1.659 PC ae C34:3 6 5.805 5.580 4.750 7.570 4.850 6.500 1.650 1.071 PC ae C36:0 6 0.521 0.526 0.342 0.682 0.465 0.583 0.118 0.114 PC ae C36:1 6 5.003 5.260 3.740 5.920 4.040 5.800 1.760 0.916 PC ae C36:2 6 9.485 8.755 7.560 12.600 8.240 11.000 2.760 1.920 PC ae C36:3 6 5.528 5.365 4.390 7.080 4.450 6.520 2.070 1.086 PC ae C36:4 6 12.562 14.350 7.840 15.000 9.030 14.800 5.770 3.236 PC ae C36:5 6 7.058 7.650 4.200 9.050 4.810 8.990 4.180 2.090 PC ae C38:0 6 1.324 1.360 0.794 1.770 0.908 1.750 0.842 0.428 PC ae C38:1 6 0.171 0.088 0.000 0.604 0.039 0.208 0.169 0.223 PC ae C38:2 6 1.020 1.007 0.553 1.610 0.762 1.180 0.418 0.363 PC ae C38:3 6 1.980 1.940 1.640 2.340 1.720 2.300 0.580 0.299 PC ae C38:4 6 7.628 8.350 5.490 9.110 5.730 8.740 3.010 1.592 PC ae C38:5 6 12.338 13.200 7.420 16.300 8.810 15.100 6.290 3.506 PC ae C38:6 6 4.462 4.170 3.090 6.170 3.460 5.710 2.250 1.228 PC ae C40:1 6 0.768 0.735 0.498 1.020 0.650 0.968 0.318 0.196 PC ae C40:2 6 0.981 1.014 0.741 1.160 0.809 1.150 0.341 0.190 PC ae C40:3 6 0.617 0.582 0.510 0.753 0.542 0.735 0.193 0.102 PC ae C40:4 6 1.443 1.410 0.979 1.930 1.050 1.880 0.830 0.419 PC ae C40:5 6 2.050 2.010 1.530 2.780 1.570 2.400 0.830 0.538 PC ae C40:6 6 2.533 2.345 2.000 3.460 2.050 3.000 0.950 0.588 PC ae C42:0 6 0.363 0.361 0.276 0.452 0.288 0.442 0.154 0.074 PC ae C42:1 6 0.185 0.187 0.108 0.241 0.172 0.213 0.041 0.044 PC ae C42:2 6 0.320 0.310 0.253 0.467 0.254 0.327 0.073 0.079 PC ae C42:3 6 0.521 0.536 0.362 0.611 0.505 0.574 0.069 0.086 PC ae C42:4 6 0.633 0.576 0.456 0.891 0.467 0.834 0.367 0.190 PC ae C42:5 6 1.598 1.615 1.150 2.140 1.170 1.900 0.730 0.411 PC ae C44:3 6 0.072 0.071 0.040 0.101 0.057 0.092 0.035 0.022 PC ae C44:4 6 0.287 0.265 0.176 0.424 0.226 0.367 0.141 0.093 PC ae C44:5 6 1.523 1.550 0.887 2.060 1.160 1.930 0.770 0.445 PC ae C44:6 6 0.893 0.860 0.638 1.130 0.747 1.120 0.373 0.207 SM (OH) C14:1 6 3.578 3.365 2.590 4.690 3.140 4.320 1.180 0.780 SM (OH) C16:1 6 1.882 1.835 1.470 2.310 1.730 2.110 0.380 0.294 SM (OH) C22:1 6 6.777 6.885 5.030 8.140 5.650 8.070 2.420 1.291 SM (OH) C22:2 6 5.658 5.745 4.200 6.740 5.270 6.250 0.980 0.883 SM (OH) C24:1 6 0.677 0.680 0.488 0.915 0.572 0.728 0.156 0.146 SM C16:0 6 80.700 83.600 55.100 94.600 72.800 94.500 21.700 15.156 SM C16:1 6 9.902 10.335 5.980 12.500 8.060 12.200 4.140 2.603 SM C18:0 6 13.000 12.600 10.100 16.700 11.800 14.200 2.400 2.253 SM C18:1 6 5.770 5.870 4.390 7.180 4.610 6.700 2.090 1.152 SM C20:2 6 0.169 0.160 0.083 0.236 0.149 0.225 0.076 0.055 SM C22:3 6 101.000 101.000 101.000 101.000 101.000 101.000 0.000 0.000 SM C24:0 6 12.023 12.010 7.970 15.800 9.150 15.200 6.050 3.450 SM C24:1 6 33.683 33.600 22.900 41.500 32.000 38.500 6.500 6.416 SM C26:0 6 0.083 0.090 0.045 0.112 0.063 0.098 0.035 0.024 SM C26:1 6 0.214 0.190 0.174 0.321 0.176 0.232 0.056 0.057 Clinical profile of the control group. There were significant differences in selenium plasma levels between all hypothyroid patients (lower levels) and control ( p  = 0.005). However, there were no differences in selenium plasma levels between the two groups of patients with hypothyroidism (multiple comparisons of mean ranks are available in Fig.  1 and Table 4 ). Fig. 1 The significant Kruskal–Wallis ANOVA test results- plasma Se and lipids levels are presented as median values with interquartile ranges (IQR, 25–75%) and minimal/maximal values. Table 4 Multiple comparisons of p values (2-tailed) of selenium plasma levels and selected lipid species in three groups: Hashimoto’s disease, non-autoimmune hypothyroidism (Hypo-non-Hashimoto), and healthy control. Se (µg/L) Kruskal–Wallis test: H ( 2. N = 41) = 11.82093 p  = .0027 Hashimoto Hypo-non- Hashimoto Control Hashimoto 1.000000 0.004944* Hypo-non-Hashimoto 1.000000 0.003781* Control 0.004944* 0.003781* LysoPC a C20:3 Kruskal–Wallis test: H ( 2. N = 41) = 6.675612 p  = .0355 Hashimoto 0.044077* 1.000000 Hypo-non-Hashimoto 0.044077* 0.157538 Control 1.000000 0.157538 PC aa C24:0 Kruskal–Wallis test: H ( 2. N = 41) = 6.544281 p  = .0379 Hashimoto 1.000000 0.039785* Hypo-non-Hashimoto 1.000000 0.279034 Control 0.039785* 0.279034 PC aa C26:0 Kruskal–Wallis test: H ( 2. N = 41) = 15.82482 p  = .0004 Hashimoto 0.210365 0.001894* Hypo-non-Hashimoto 0.210365 0.227979 Control 0.001894* 0.227979 PC aa C40:1 Kruskal–Wallis test: H ( 2. N = 41) = 31.40706 p  = .0000 Hashimoto 1.000000 0.000443* Hypo-non-Hashimoto 1.000000 0.003090* Control 0.000443* 0.003090* PC ae C30:1 Kruskal–Wallis test: H ( 2. N = 41) = 8.596205 p  = .0136 Hashimoto 0.908467 0.025399* Hypo-non-Hashimoto 0.908467 0.310172 Control 0.025399* 0.310172 PC ae C34:0 Kruskal–Wallis test: H ( 2. N = 41) = 7.436659 p  = .0243 Hashimoto 0.370555 0.031015* Hypo-non-Hashimoto 0.370555 0.688991 Control 0.031015* 0.688991 PC ae C36:4 Kruskal–Wallis test: H ( 2. N = 41) = 8.468897 p  = .0145 Hashimoto 0.020913* 0.250969 Hypo-non-Hashimoto 0.020913* 1.000000 Control 0.250969 1.000000 PC ae C42:0 Kruskal–Wallis test: H ( 2. N = 41) = 17.34746 p  = .0002 Hashimoto 1.000000 0.000601* Hypo-non-Hashimoto 1.000000 0.014468* Control 0.000601* 0.014468* Only significant values (marked with *) are presented. The significant Kruskal–Wallis ANOVA test results- plasma Se and lipids levels are presented as median values with interquartile ranges (IQR, 25–75%) and minimal/maximal values. Multiple comparisons of p values (2-tailed) of selenium plasma levels and selected lipid species in three groups: Hashimoto’s disease, non-autoimmune hypothyroidism (Hypo-non-Hashimoto), and healthy control. Only significant values (marked with *) are presented. Interestingly, lysoPC a C20:3 was lower ( p  = 0.04) in the Hypo-non-Hashimoto group than in the Hashimoto’s disease group and the control group (CG). PC aa C26:0 ( p  = 0.002), PC ae C30:1 ( p  = 0.025), PC ae C34:0 ( p  = 0.03), as well as PC aa C24:0 ( p  = 0.04), were higher in the group with Hashimoto’s disease than in the CG. There were no significant differences in the two hypothyroid groups for these lipids. PC aa C40:1 ( p  = 0.0004), as well as PC ae C42:0 ( p  = 0.0006), were higher in all hypothyroid patients in comparison to CG, and PC ae C36:4 was higher ( p  = 0.02) i n the group with the Hashimoto’s disease than in the group Hypo-non-Hashimoto, but not in CG, as it is seen in Fig.  1 and Table 4 . All values, both significant and not significant regarding the multiple comparison p values (two-sided) of plasma selenium levels and selected lipid species in the three groups are presented in supplementary Table S2 . As it is seen in Table 5 , PC aa C26:0 and PC aa C40:1 were negatively correlated with plasma selenium concentrations. These lipid species also presented significant differences in the Kruskal–Wallis ANOVA test (see above). Other lipids that were negatively correlated with plasma selenium concentrations but did not present any significant differences between the three groups in the Kruskal–Wallis ANOVA test were PC aa C32:0, PC ae C30:0, PC ae C36:5, SM C18:0, and SM C18:1. Table 5 The Spearman rank order – correlations of plasma selenium levels with lipid species. Only significant values are presented. Variable Se (µg/L) HDL cholesterol (mg/dL) − 0.323333 Triglycerides (mg/dL) − 0.386700 PC aa C26:0 − 0.421332 PC aa C32:0 − 0.311255 PC aa C40:1 − 0.496637 PC ae C30:0 − 0.355506 PC ae C36:5 − 0.319829 SM C18:0 − 0.354579 SM C18:1 − 0.312337 The Spearman rank order – correlations of plasma selenium levels with lipid species. Only significant values are presented. In the multiple linear regression analyses (Table 6 ), plasma selenium levels showed a negative relationship with the presence of hypothyroidism. PC aa C24:0, PC aa C26:0, PC ae C30:1, PC ae C34:0, PC ae C36:4, PC ae C42:0 were positively associated with the presence of hypothyroidism. Table 6 Multiple linear regression analyses of the association between the presence of hypothyroidism and plasma selenium levels as well as selected lipid species. Regression summary N = 41 Se (µg/L) b* Std.Err. of b* b Std.Err. of b t(39) p -value Hashimoto 1 Hypo-non-Hashimoto 2 control 3 0.413249 0.145816 14.65842 5.172253 2.834049 0.007243 PC aa C24:0 Hashimoto 1 Hypo-non-Hashimoto 2 control 3 − 0.338973 0.150648 − 22.7159 10.09553 − 2.25010 0.030159 PC aa C26:0 Hashimoto 1 Hypo-non-Hashimoto 2 control 3 − 0.572336 0.131308 − 38.3971 8.80924 − 4.35873 0.000092 PC ae C30:1 Hashimoto 1 Hypo-non-Hashimoto 2 control 3 − 0.462195 0.141998 − 31.5287 9.68642 − 3.25494 0.002348 PC ae C34:0 Hashimoto 1 Hypo-non-Hashimoto 2 control 3 − 0.370008 0.148764 − 0.149118 0.059954 − 2.48722 0.017259 PC ae C36:4 Hashimoto 1 Hypo-non-Hashimoto 2 control 3 − 0.408951 0.146126 − 2.64950 0.946718 − 2.79862 0.007936 PC ae C42:0 Hashimoto 1 Hypo-non-Hashimoto 2 control 3 − 0.503739 0.138328 − 33.9922 9.33434 − 3.64163 0.000786 Multiple linear regression analyses of the association between the presence of hypothyroidism and plasma selenium levels as well as selected lipid species.

It is known that a wide range of hormones regulate lipid metabolism simultaneously in a time-specific manner. Thyroid hormones regulate and affect both cholesterol and fatty acid metabolism. They stimulate fatty acid synthesis (lipogenesis), triglyceride breakdown (lipolysis), fatty acid oxidation, cholesterol synthesis, and low-density lipoprotein (LDL) receptors. Genes involved in lipogenesis in the liver and positively regulated by HT include fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), spot14 protein, and malate enzyme (ME) genes. Fatty acid oxidation-related genes positively regulated by HT include carnitine acyltransferase (CPT), acyl-CoA translocase (TAC), and long-chain fatty acid oxidase (AOX) genes. Cholesterol synthesis is influenced by T3 by stimulating the expression of the hydroxymethylglutaryl-CoA reductase (RHMG) gene and the activity of this enzyme. Inhibition by T3 of the expression of cholesterol 7α-hydroxylase (CYP7A1) contributes to the reduction of bile acid synthesis 24 . Very recently, Zhang et al. 25 provided new insight into hormones regulating lipid metabolism and highlighted the role of thyroid hormone receptors (THR) in lipid metabolism. Although the effect of THRs and subsequent pathways in lipid metabolism is still under investigation, this research, citing animal studies, emphasizes that THs not only directly regulate lipogenic gene expression but also affect the activity of other transcription factors, such as sterol regulatory element binding protein-1c (SREBP1c) and carbohydrate-responsive element-binding protein (ChREBP), indirectly influencing hepatic lipogenesis 26 . THs promote the lipolysis of white adipose tissue, which is a source of circulating free fatty acids (FFAs), induces the protein transporter expression such as fatty acid transporter proteins (FATPs), liver fatty acid-binding proteins (L-FABPs) and fatty acid translocase 27 . Thyroid hormones, such as thyroxine (T4) and triiodothyronine (T3), exert their effects by binding to specific nuclear receptors, which then modulate gene expression 24 . Proper membrane structure is essential for the function and localization of these receptors. Its integrity and fluidity are precisely ensured by, for example, glycerophospholipids 28 . The membrane of thyrocytes contains thyroid peroxidase (TPO), an enzyme involved in the synthesis of thyroid hormones, and proteins involved in the processes of iodine uptake, incorporation of this element into thyroglobulin, as well as the release of thyroid hormones into the bloodstream and their transport 29 . In addition, glycerophospholipids may play a role in immune system recognition and response, so changes in membrane composition could potentially affect antigen presentation and immune responses, contributing to the development of autoimmune diseases such as Hashimoto’s 30 . The imbalance between free radical production and antioxidant defense, is associated with damage to a wide range of molecular species, including lipids, proteins and nucleic acids 31 . Oxidative damage affecting glycerophospholipids, among others, leads to lipid peroxidation and the release of inflammatory molecules, exacerbating thyroid dysfunction 30 . Lipid peroxidation occurs when a hydroxyl radical strips an electron from an unsaturated fatty acid. The unstable lipid radical that forms can then react with oxygen to form a fatty acid peroxyl radical can react with another unsaturated fatty acid. As a result, the generated fatty acid hydroperoxide and new lipid radical promote damage to cell membranes 32 . Free radicals play a very important role in the functioning and regulation of the immune system 33 . They intensify the activation of T lymphocytes and cause leukocyte cells to fuse with the endothelium, allowing them to move from the circulatory system to the site of the inflammatory response. Reactive oxygen species are signaling molecules, in their action very similar to hormone messengers and hormones themselves 34 . Oxidative stress is implicated in multiple diseases, including diabetes, obesity, neurological diseases, cardiovascular disease and cancer 35 . Research on oxidative stress indicates associations of thyroid diseases, including thyroid gland tumors, as well as autoimmune thyroid disease 36 , 37 . Hashimoto’s thyroiditis is likely related to iodide-mediated oxidative stress and inflammation 38 . Thyroid disorders may initiate or increase ROS release and oxidative stress, enhancing oxidative damage, which appears to be involved in both the initiation and progression of carcinogenesis 37 . With advances in analytical methodologies and techniques for determining compounds of indisputable relevance in health and disease states, such as lipids, there has been an increased interest in individual metabolites. Lipidomics, belonging to the field of metabolomics, may be used to investigate metabolic changes in various diseases 39 . Recent studies have shown an association between the results of lipidomic profiling and selected disease onset and progression 40 , 41 . Lipidomics involves complex lipidome analysis and is quite challenging due to the vast number of lipid species. Owing to their considerable structural diversity, lipids are important players in various complex physiological processes where they execute important functions, acting as cellular membrane components, signaling mediators, energy reserve molecules, and endocrine regulators 42 . It has been revealed that not only the main “clinical” lipids (TG, CHOLs) are useful during routine diagnostics and treatment, but there is also a great hope among scientists that analysis of the human lipidome will help in detecting and monitoring an increasing number of human diseases. An essential advantage of lipidomics is the ability to identify specific plasma lipid abnormalities, e.g., changes in molecular species containing particular-chain-length fatty acids. The specific molecular changes would remain undetected if one were using the enzymatic lipid assays that are routinely applied in clinical laboratories to determine total lipid (TL) content in serum. In our study, the following lipid classes: acylcarnitines (more specifically, a plasma acylcarnitine profile can aid in the diagnosis of organic acidemias in addition to fatty acid oxidation disorders), glycerophospholipids (structural components of biological membranes, important constituents of lipoproteins, performing functions in other cellular processes such as signal induction and transport), and sphingomyelins (having significant structural and functional roles in the cell, as plasma membrane components and as participants in many signaling pathways) were identified and quantified. Our results suggest that among almost two hundred metabolites, which we could quantify using targeted metabolomics analysis, only a few correlated with hypothyroidism and Hashimoto disease (see Tables 4 , 5 , and 6 ). Although glycerophospholipids are known to dominate cell membranes, providing stability, fluidity and permeability, are required for the proper function of membrane proteins, receptors and ion channels, and act as reservoirs of second messengers and their precursors, not all species of this broad class of lipids are well understood in the context of interactions with thyroid hormones. The different combinations of glycerophospholipid head groups and fatty acyl chains give rise to thousands of molecular species 43 . Among them are glycerophospholipids such as PC ae C30:1, PC ae C36:5, and PC ae C42:0. According to our best knowledge, no studies describe a significant association of these molecules in any disease. Due to the complexity of metabolism and insufficient research, there is a lack of thorough information on the function of these specific lipids in the human body. There is no conclusive data that glycerophospholipids have a direct effect on the onset and development of thyroid diseases, such as hypothyroidism or Hashimoto’s, which are complex and often multifactorial, involving factors such as genetics, immune responses, hormonal imbalances, and also environmental factors 44 , 45 . Although PC ae C34:0 has not been previously linked to hypothyroidism or Hashimoto’s, this lipid has been linked to other diseases. PC ae C34:0 levels have been characterized in three papers on Alzheimer’s disease (AD), colorectal cancer (CRC), and VZV (chickenpox and hemiplegia virus) meningitis. In a study performed by Huo et al. 46 concerning Alzheimer’s disease, elevated serum levels of this lipid measured prior to diagnosis (AD) predicted a faster decline in global cognition and three cognitive domains (episodic memory, perceptual speed, semantic memory). At the same time, it showed protective effects on neuropathology in brain tissue samples. It is also suggested that this lipid may be a predictor of high risk of colorectal cancer recurrence in the next 6 months after hepatectomy 47 . Furthermore, PC ae C34:0 can be considered as a biomarker in the diagnosis of meningitis resulting from VZV since, in addition to the other lipids mentioned, its concentration characterized inflammation and pathological processes in parenchymal cells of the central nervous system, without a clear effect on the number of leukocytes in the cerebrospinal fluid 48 . PC ae C36: 4 was characterized in the study on determining metabolic changes after metformin use to treat type 2 diabetes mellitus (T2DM) 49 . A significant decrease in phosphatidylcholine PC ae C36:4 was demonstrated not with the first dose of this drug but with its prolonged use in the 4–6 weeks range. PC aa C36:4 was also demonstrated to be positively associated with BMI 50 . Interestingly, in our study the analyses of the association between the presence of hypothyroidism and plasma selenium levels as well as selected lipid species revealed significant values for phosphatidylcholines (PCs) which are among the major constituents of cell membranes and represent important components of lipoproteins 51 . Out of 145 different lipid molecules analyzed qualitatively by TLA in the present study for only six PCs, i.e. PC aa C24:0, PC aa C26:0, PC ae C30:1, PC ae C34:0, PC ae C36:4, PC ae C42:0 (aa indicating two acyl-bound and ae indicating one acyl- and one alkyl-bound fatty acids) the mentioned significant associations were found. Most research on sphingomyelin (SM) has focused on its role in cell membrane structure, myelin sheath formation, neurological functions, and various cell signaling pathways 52 – 55 . Although sphingolipids, including sphingomyelins, are known to be involved in cell signaling and membrane functions, their specific involvement in thyroid diseases, such as hypothyroidism or Hashimoto’s thyroiditis, has not been thoroughly studied or established. Sphingolipids, like glycerophospholipids, are major components of cell membranes, contributing to their structural integrity and fluidity. They are particularly abundant in the outer layer of the plasma membrane, where they help form lipid rafts—microdomains that play a role in signaling, protein transport, and membrane organization. They participate in intracellular membrane transport and vesicle formation during endocytosis, exocytosis, and vesicular transport. Sphingolipids are involved in various signaling pathways that regulate cell growth, differentiation, survival, and apoptosis (programmed cell death). They can modulate immune responses by affecting immune cell activity and cytokine secretion 56 . Both the de novo synthesis of sphingolipids and the sphingomyelinase pathway are important in the pathogenesis of some auto-immune disorders, e.g., autoimmune encephalomyelitis 57 or arthritis 58 . SMs are major components of cell membranes, particularly abundant in the outer layer of the plasma membrane. Along with cholesterol, SMs contribute to membrane stability, fluidity, and lipid raft formation. This interaction is vital for maintaining the proper balance between rigidity and elasticity of cell membranes. It is also a key component of myelin sheaths in neurons. Contributing to the insulation and integrity of nerve fibers, it enables efficient transmission of nerve signals. Sphingomyelin can act as a reservoir of enzymes involved in sphingolipid metabolism, such as sphingomyelinases. As a result of their action, bioactive lipid molecules can be formed, including ceramides, which are involved in cell signaling 59 . Disruption of sphingomyelin metabolism is associated with various diseases, including Niemann-Pick disease, lysosomal storage disorder, and arteriosclerosis, in which the accumulation of sphingomyelin in blood vessels can contribute to the formation of atherosclerotic plaques 60 , 61 . Research revealed a significant association of C18:1 sphingomyelin (SM) with multisite musculoskeletal pain (MSMP) 62 with alcohol use and smoking 63 , liver cirrhosis 64 , and also in association with other sphingomyelins, contribute to T2D through effects on BMI 50 . Elevated levels of SM C18 have been reported as a probable predictor of Alzheimer’s disease 65 , diagnosis of insulin-related disorders, and especially type 1 diabetes mellitus (T1DM) and latent autoimmune diabetes in adults (LADA) 66 . In addition, increased levels of this sphingomyelin were detected in a study group with endocrine hypertension (EHT) 67 , hyperglycemic patients were more likely to develop chronic kidney disease (CKD) 68 , and in patients with polycystic ovary syndrome (PCOS) 69 . Significantly reduced levels of SM C18:1 were reported in studies 70 concerning only peritoneal fluid samples from patients diagnosed with endometriosis. To the best of our knowledge, the present study is the first to demonstrate the possible association of several components of the human lipidome with hypothyroidism. Our finding is significant as it may provide a basis for further investigation to clarify the role of selected lipid molecules in hypothyroidism. In our current study, we were interested in whether Se, a micronutrient whose excess is just as problematic as deficiency, may be associated with particular lipid species linked to hypothyroidism. The relationship between hypothyroidism and selenium levels is complex and bidirectional—hypothyroidism is associated with an increased risk of selenium deficiency. In contrast, selenium deficiency can exacerbate thyroid dysfunction because selenium is required to convert the inactive thyroid hormone T4 (thyroxine) into the active form T3 (triiodothyronine). Without sufficient selenium, this conversion process may be impaired, contributing to the symptoms of hypothyroidism. In individuals with hypothyroidism, the body’s metabolic rate is decreased, leading to reduced absorption of nutrients, including selenium, from the gastrointestinal tract—this can result in a feedback loop, further lowering selenium levels in the bloodstream. Selenium is thus regarded as one of the most potent antioxidants. The role of Se-containing selenoenzymes and selenoproteins is to speed up the oxidation reaction of proteins scavenging reactive oxygen species. Se protects the body from oxidative stress, which can cause immune disorders, cardiovascular disease, and cancer. Selenium deficiencies can lead to a significant weakening of the immune response. This is due to, among other things, a decrease in the activity of T lymphocytes, macrophages, and NK cells. Studies indicate that selenium supplementation causes a decrease in anti-thyroid peroxidase antibodies (anti-TPO) and also an increase in the ratio between FT3 and FT4 (selenium is an important component of the enzyme that converts thyroxine T4 into triiodothyronine T3) 71 . Khorasani et al. 71 investigated Se status in patients categorized into two groups depending on the type of diagnosis, i.e., hypothyroidism and autoimmune thyroiditis, and found significant differences in serum concentrations of Se between hypothyroid patients (with a lower concentration of Se) and controls. However, no relationship was found between the type of thyroid disease and a pronounced selenium deficiency. The findings of Stojsavljević et al. 72 indicated apparent differences in Se profiles between hypothyroidism and healthy subjects. However, in contrast to studies of Khorasani et al. 71 significantly higher concentrations of selenium in the group of respondents suffering from hypothyroidism compared with healthy subjects were found. Studies on the relationship between body selenium levels and hyperlidpidemia emphasize the role of oxidative stress and the inflammatory response 73 . This is not the only possible pathway, as selenium may interact with other elements and this may cause dyslipidaemia by encouraging the release of lipids from the liver and adipose tissues, resulting in decreased activity of antioxidant enzymes such as superoxide dismutase and catalase, increased lipid peroxide levels in the liver and kidneys and markers of abnormal liver function. Oxidation of cell membranes can potentially cause hepatotoxic effects that affect liver function and reduce lipid production in hepatocytes 74 . Studies showed that selenium deficiency increases lipid peroxidation in the membranes, and clearly leads to the cell death. Research confirmed that the lipid hydroperoxides, play a causative role in the oxidative damage to cells induced by selenium deficiency 75 . Recent animal studies revealed that selenium deficiency in diet may adversely influence the fatty acid profile (e.g., conversion of linolenic acid (ALA) to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), resulting in the unbeneficial n-6/n-3 ratio in tissue lipids) 76 . A meta-analysis based on human studies that explored Se levels and the effect of Se supplementation on lipid profile (including total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), very low-density lipoprotein (VLDL)) measurements) suggested that the effect of selenium supplementation on the serum levels of TG and VLDL was marginally significant and that the effect of selenium supplementation on lipid profile was negative 77 . While it has been reported that Se may be associated with lipid levels, the available data seem to be conflicting 78 . Examining the relation of serum selenium concentrations with serum lipids in large, Se-replete men and women from the US revealed the association of Se and TC, LDL-C, HDL-C, TGs, apo B, and apo A-I. However, the cause-and-effect relations and the potential mechanisms underlying these associations remain unknown 79 . About two decades ago, a considerable number of Polish inhabitants had a relatively low concentration of Se in blood plasma—about 50–55 μg/l, and the calculated daily dietary intake was about 30–40 μg/day 80 . Selenium deficiency was diagnosed by measuring the serum or plasma selenium level, which should be at least 85 μg/L 81 . Recent studies on the Polish population report Se levels of approximately 79 μg/L in healthy adults 82 . Although various national and international guidelines often provide reference ranges, there is no specific data on Se levels in compensated (well-controlled) hypothyroidism in the Polish population of adults.

The present preliminary study is the first to demonstrate the association of several components of the human lipidome with hypothyroidism in relation to the total plasma selenium content. Different lipidome profiles were identified in healthy and hypothyroid patients regardless of the cause of that condition. Our studies emphasize the contributing role of Se in altered lipid metabolism in patients with hypothyroidism. The association between Se and particular lipid molecules was modified by thyroid pathology. Out of 145 different lipid molecules analyzed qualitatively by TLA in the present study only six PCs, i.e. PC aa C24:0, PC aa C26:0, PC ae C30:1, PC ae C34:0, PC ae C36:4, PC ae C42:0 were positively associated with the presence of hypothyroidism. Plasma selenium levels showed a negative relationship with the presence of hypothyroidism. Subsequent studies are required to elucidate the mechanisms of such association and clarify the role of particular lipid species in hypothyroidism.

Lipids are diverse and multifunctional molecules integral to cellular structure, signaling, and function. Studying lipid species in biological samples, including human body fluids or tissues, provides valuable insights into biology, physiology, disease mechanisms, and potential ways for therapeutic intervention. Research on human lipidome, i.e., the total lipid content within a cell, organ, or biological system, can be used in risk assessment model development, disease diagnosis, and its monitoring 1 . Understanding how lipids function and how to control their activity also offers the potential to develop novel treatments for controlling numerous diseases. The involvement of lipids in metabolic pathways and their role in the pathology of diseases related to the endocrine system is increasingly understood 2 . Hormones modulate every pathway in lipoprotein metabolism, influence the expression of lipoprotein receptors, the production of apolipoproteins, the activity of plasma lipoprotein-modifying enzymes, and the blood concentrations of substrates for triglycerides (TGs) synthesis, such as fatty acids and glucose. Therefore, it is anticipated that endocrine disruption, including hypothyroidism, alters the lipid profile 3 . Hypothyroidism is a common endocrine disorder resulting from a deficiency of thyroid hormones (TH). Worldwide, iodine deficiency is the most common cause of hypothyroidism; however, in Poland and other areas of adequate iodine intake, chronic autoimmune thyroiditis—the Hashimoto’s disease also known as the Hashimoto thyroiditis is the primary reason for hypothyroidism 4 , 5 . Although it has been suggested that overt hypothyroidism results in elevated levels of low-density lipoprotein (LDL)- cholesterol, high-density lipoprotein (HDL)- cholesterol, and triglycerides (TGs) in serum 6 , the relationship between subclinical hypothyroidism (SCH) and blood lipid metabolism remains controversial, and the definite association between SCH and routinely measured blood lipid levels such as TC (total cholesterol), LDL-C, and HDL-C has not been confirmed 7 . In contrary, another study revealed that the total cholesterol level in SCH was positively correlated with the level of TSH 8 . Recently, several studies have shown that thyroid hormones can affect incident dyslipidemia in a general euthyroid population 9 , 10 . Low but normal FT3 was associated with high dyslipidemia risk, especially for elevated TC and LDL-C, and normal TSH had a weak positive effect on the incidence of reduced HDL-C 9 . In another study, positive and significant relationships between TSH level and TG level as well as between FT4 level and TC, LDL-C, and HDL-C cholesterol levels were demonstrated 10 . Since levothyroxine (LT4) replacement therapy reduces levels of TSH, it is well known that the treatment could also reduce TC and LDL-C in hypothyroidic patients, including those with mild SCH 11 , 12 . The current standard of care for hypothyroidism is levothyroxine (LT4) monotherapy to reduce levels of TSH within its reference range. Once a patient’s thyroid hormones are in the normal range, the Endocrine Society clinical practice guideline being the first to focus on lipid management in patients with endocrine disorders, recommends re-evaluating the lipid profile 12 . Since thyroid hormones modulate a number of pathways involved in lipid metabolism, it is doubtful whether a basic blood lipid profile assessment in hypothyroidic patients with biochemical euthyroidism (i.e. thyroid hormones and TSH within the normal range) brings adequate information on the complexity of lipids activity and turnover. Using a modern lipidomic approach, we intended to find out to what extent and which specific lipid molecules differ quantitatively in healthy and hypothyroid adults with biochemical euthyroidism and without any comorbidities. To the best of our knowledge, human lipidome alterations have not been studied in such patients with well-controlled hypothyroidism (i.e. stable TSH levels within the normal range on the appropriate dose of LT4 replacement therapy). Furthermore, other factors may mediate the interplay between the action of thyroid hormones and lipid compounds, considering that thyroid hormones play an important role in maintaining energy homeostasis in the body. The essential trace element selenium (Se) is known to influence such a balance 13 . There are many reports on the disruption of the physiological levels of Se in the body that adversely affect the functioning of cells and tissues, which can lead to the development of hypothyroidism 14 . Selenium is required for the antioxidant function and the metabolism of thyroid hormones, and its intake has been associated with autoimmune disorders 15 . Duntas et al. 16 investigated the effect of selenium treatment in the form of selenomethionine in patients with autoimmune thyroiditis by affecting the levels of TPOAb and TgAb after 3 and 6 months. In the supplement group TPOAb levels decreased by 46% after 3 months and by 46% after 6 months compared to a decrease of only 21% and 27%, respectively, at 3 and 6 months in the group treated with thyroxine. Nevertheless, there was no statistically significant statistically significant difference in TPOAb levels or in the levels of TSH, free T4 and T3 between the two groups. There were no significant changes of antibodies against thyroglobulin levels between these groups. In turn, another randomized double-blind placebo-controlled trial investigating whether adding selenium to standard LT4 treatment in Hashimoto’s thyroid patients can lead to improved quality of life and reduced autoimmune disease activity did not justify the routine use of selenium supplementation in patients with Hashimoto’s disease, as selenium supplementation for 12 months, compared to placebo, did not improve patients’ quality of life, LT4 dose or FT3I / FT4 ratio 17 . Despite some inconsistencies presented in the literature regarding either low or high Se status in hypothyroid patients, there is clear evidence of a close relationship between this element and thyroid health and function 18 , 19 . Recently, integrated analysis of miRNAs and the proteome in SCH mice highlighted an interesting associations between some miRNAs and proteins, including selenium-binding protein 2, which contributes to a better understanding of lipid metabolism disorders in subclinical hypothyroidism 20 . Although there are some data indicating that no strong correlation exists between serum selenium levels and lipid profile in humans without any pathology of the thyroid gland 21 , the associations between Se in plasma and the plasma lipidome in patients with hypothyroidism remain unknown. Our cohort study aimed to reveal which lipid species are altered in hypothyroidic patients with biochemical euthyroidism who present normal serum lipid profiles (LDL-cholesterol, HDL-cholesterol, total cholesterol, and triglycerides). Furthermore, we intended to investigate whether selenium levels in these patients are associated with the content of individual lipid molecules and whether the possible Se-lipidome association is modified by thyroid status. This may provide a theoretical basis for the better understanding and control of thyroid dysfunctions and related lipid imbalances, as well as it may help to reveal more about human metabolism.

Supplementary Information 1. Supplementary Information 2. Supplementary Information 1. Supplementary Information 2.